GENinCode (LON:GENI) Trading Down 7.1% – Time to Sell?

GENinCode Plc (LON:GENI) was down 7.1% during trading on Thursday . The stock traded as low as GBX 0.86 and last traded at GBX 0.93. 3,936,327 shares were traded during mid-day trading, a decline of 38% from the average daily volume of 6,329,568 shares. The stock had previously closed at GBX 1.

GENinCode Stock Down 7.1%

The business has a fifty day moving average of GBX 1.09 and a 200 day moving average of GBX 1.42. The stock has a market cap of £6.74 million, a price-to-earnings ratio of -0.40 and a beta of 0.59. The company has a debt-to-equity ratio of 117.74, a current ratio of 0.93 and a quick ratio of 15.88.

GENinCode (LON:GENI) last posted its earnings results on Monday, June 8th. The company reported GBX (2.08) earnings per share (EPS) for the quarter. The business had revenue of GBX 308 million during the quarter. GENinCode had a negative net margin of 185.47% and a negative return on equity of 409.40%. On average, equities analysts predict that GENinCode Plc will post -7.1299999 earnings per share for the current year.

GENinCode Company Profile

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U.

GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.